Umbilical cord blood cells for treatment of cerebral palsy; Timing and treatment options

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Cerebral palsy is the most common cause of physical disability in children, and there is no cure. Umbilical cord blood (UCB) cell therapy for the treatment of children with cerebral palsy is currently being assessed in clinical trials. Although there is much interest in the use of UCB stem cells for neuroprotection and neuroregeneration, the mechanisms of action are not fully understood. Further, UCB contains many stem and progenitor cells of interest, and we will point out that individual cell types within UCB may elicit specific effects. UCB is a clinically proven source of hemotopoietic stem cells (HSCs). It also contains mesenchymal stromal cells (MSCs), endothelial progenitor cells (EPCs), and immunosupressive cells such as regulatory T cells (Tregs) and monocyte-derived supressor cells. Each of these cell types may be individual candidates for the prevention of brain injury following hypoxic and inflammatory events in the perinatal period. We will discuss specific properties of cell types in UCB, with respect to their therapeutic potential and the importance of optimal timing of administration. We propose that tailored cell therapy and targeted timing of administration will optimize the results for future clinical trials in the neuroprotective treatment of perinatal brain injury.

Original languageEnglish
Pages (from-to)333-344
Number of pages12
JournalPediatric Research
Volume83
Issue number1-2
DOIs
Publication statusPublished - 1 Jan 2018

Cite this

@article{91fd501f4dba42638bb69345458e8337,
title = "Umbilical cord blood cells for treatment of cerebral palsy; Timing and treatment options",
abstract = "Cerebral palsy is the most common cause of physical disability in children, and there is no cure. Umbilical cord blood (UCB) cell therapy for the treatment of children with cerebral palsy is currently being assessed in clinical trials. Although there is much interest in the use of UCB stem cells for neuroprotection and neuroregeneration, the mechanisms of action are not fully understood. Further, UCB contains many stem and progenitor cells of interest, and we will point out that individual cell types within UCB may elicit specific effects. UCB is a clinically proven source of hemotopoietic stem cells (HSCs). It also contains mesenchymal stromal cells (MSCs), endothelial progenitor cells (EPCs), and immunosupressive cells such as regulatory T cells (Tregs) and monocyte-derived supressor cells. Each of these cell types may be individual candidates for the prevention of brain injury following hypoxic and inflammatory events in the perinatal period. We will discuss specific properties of cell types in UCB, with respect to their therapeutic potential and the importance of optimal timing of administration. We propose that tailored cell therapy and targeted timing of administration will optimize the results for future clinical trials in the neuroprotective treatment of perinatal brain injury.",
author = "McDonald, {Courtney A.} and Fahey, {Michael C.} and Graham Jenkin and Miller, {Suzanne L.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1038/pr.2017.236",
language = "English",
volume = "83",
pages = "333--344",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Nature Publishing Group",
number = "1-2",

}

Umbilical cord blood cells for treatment of cerebral palsy; Timing and treatment options. / McDonald, Courtney A.; Fahey, Michael C.; Jenkin, Graham; Miller, Suzanne L.

In: Pediatric Research, Vol. 83, No. 1-2, 01.01.2018, p. 333-344.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Umbilical cord blood cells for treatment of cerebral palsy; Timing and treatment options

AU - McDonald, Courtney A.

AU - Fahey, Michael C.

AU - Jenkin, Graham

AU - Miller, Suzanne L.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Cerebral palsy is the most common cause of physical disability in children, and there is no cure. Umbilical cord blood (UCB) cell therapy for the treatment of children with cerebral palsy is currently being assessed in clinical trials. Although there is much interest in the use of UCB stem cells for neuroprotection and neuroregeneration, the mechanisms of action are not fully understood. Further, UCB contains many stem and progenitor cells of interest, and we will point out that individual cell types within UCB may elicit specific effects. UCB is a clinically proven source of hemotopoietic stem cells (HSCs). It also contains mesenchymal stromal cells (MSCs), endothelial progenitor cells (EPCs), and immunosupressive cells such as regulatory T cells (Tregs) and monocyte-derived supressor cells. Each of these cell types may be individual candidates for the prevention of brain injury following hypoxic and inflammatory events in the perinatal period. We will discuss specific properties of cell types in UCB, with respect to their therapeutic potential and the importance of optimal timing of administration. We propose that tailored cell therapy and targeted timing of administration will optimize the results for future clinical trials in the neuroprotective treatment of perinatal brain injury.

AB - Cerebral palsy is the most common cause of physical disability in children, and there is no cure. Umbilical cord blood (UCB) cell therapy for the treatment of children with cerebral palsy is currently being assessed in clinical trials. Although there is much interest in the use of UCB stem cells for neuroprotection and neuroregeneration, the mechanisms of action are not fully understood. Further, UCB contains many stem and progenitor cells of interest, and we will point out that individual cell types within UCB may elicit specific effects. UCB is a clinically proven source of hemotopoietic stem cells (HSCs). It also contains mesenchymal stromal cells (MSCs), endothelial progenitor cells (EPCs), and immunosupressive cells such as regulatory T cells (Tregs) and monocyte-derived supressor cells. Each of these cell types may be individual candidates for the prevention of brain injury following hypoxic and inflammatory events in the perinatal period. We will discuss specific properties of cell types in UCB, with respect to their therapeutic potential and the importance of optimal timing of administration. We propose that tailored cell therapy and targeted timing of administration will optimize the results for future clinical trials in the neuroprotective treatment of perinatal brain injury.

UR - http://www.scopus.com/inward/record.url?scp=85042160056&partnerID=8YFLogxK

U2 - 10.1038/pr.2017.236

DO - 10.1038/pr.2017.236

M3 - Review Article

VL - 83

SP - 333

EP - 344

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 1-2

ER -